Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist
Pegg, Cassandra L., Cooper, Leanne T., Zhao, Jing, Gerometta, Michael, Smith, Fiona M., Yeh, Michael, Bartlett, Perry F., Gorman, Jeffrey J., Boyd, Andrew W.Volume:
7
Language:
english
Journal:
Scientific Reports
DOI:
10.1038/s41598-017-06685-z
Date:
December, 2017
File:
PDF, 1.16 MB
english, 2017